Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Authors: Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue, Jiwei Huang

Published: 2019-10-30

DOI: 10.1186/s40880-019-0405-5

Source: Full article

---

Abstract

No abstract found.